Role of bone marrow examination in staging Hodgkin's disease: experience in México
Authors: Gómez-Almaguer, D.1; Ruiz-Argüelles, G.J.; López-MartÍnez, B.; Estrada, E.; Lobato-Mendiza´bal, E.2; Jaime-Pérez, J.C.1
Source: Clinical & Laboratory Haematology, Volume 24, Number 4, August 2002 , pp. 221-223(3)
Publisher: Blackwell Publishing
Abstract:
Summary We assessed the value of bone marrow biopsy prospectively in a group of 91 individuals with Hodgkin's disease. The median age of our population was 29 years (range 4-87 years); 59 were males. Most patients (45%) had nodular sclerosing disease and most patients (44%) were in pathological stage II at diagnosis. The bone marrow biopsy showed infiltration by Hodgkin's disease in only three individuals (3.3%); two of these patients displayed constitutional symptoms and had been assigned to stage III before the biopsy. In one case, bone marrow biopsy was the diagnostic procedure, which was performed as part of the investigation of fever of unknown origin. Follow-up periods ranged between 1 and 117 months (median 16 months). All patients achieved complete remission, seven patients relapsed and four were given autologous stem cell transplants. The median survival of the whole group was 117 months, while the 3500-day survival was 76%. As bone marrow biopsy was the diagnostic procedure in one case, bone marrow biopsy was a useful staging procedure in only 2.2% of patients (two out of 90 patients). We suggest that bone marrow biopsy should be only be performed as a staging procedure in a selected subset of patients with Hodgkin's disease (clinical stage III, B symptoms, etc.).Keywords: Hodgkin's disease; staging; bone marrow; biopsy
Document Type: Research article
DOI: 10.1046/j.1365-2257.2002.00450.x
Affiliations: 1: Hospital Universitario de Monterrey, Monterrey, 2: Centro de Hematología y Medicina Interna de Puebla, Puebla and

Click here for Page Help